# EDGAR Filing Document

**Accession Number:** 0002053118
**File Stem:** 0000000000-25-007952
**Filing Date:** 2025-7
**Character Count:** 4210
**Document Hash:** 2382a882ea1057acbbe0c82ffc008adb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007952.hdr.sgml**: 20250924

**ACCESSION NUMBER**: 0000000000-25-007952

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250729

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FirstVitals Inc.
- **CENTRAL INDEX KEY:** 0002053118
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 994891274
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 024-12598

**BUSINESS ADDRESS:**
- **STREET 1:** 2605 CAMINO TASSAJARA
- **STREET 2:** UNIT 2500
- **CITY:** DANVILLE
- **STATE:** CA
- **ZIP:** 94526
- **BUSINESS PHONE:** 8009228844

**MAIL ADDRESS:**
- **STREET 1:** 2605 CAMINO TASSAJARA
- **STREET 2:** UNIT 2500
- **CITY:** DANVILLE
- **STATE:** CA
- **ZIP:** 94526
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001214659-25-005420

## Text-Extract

```

                                                           July 29, 2025

Ernest Lee
Chief Executive Officer
FirstVitals, Inc.
2605 Camino Tassajara #2500
Danville, CA 94526

       Re: FirstVitals, Inc.
           Amendment No. 4 to Offering Statement on Form 1-A
           Filed July 21, 2025
           File No. 024-12598
Dear Ernest Lee:

     We have reviewed your amended offering statement and have the following
comments.

       Please respond to this letter by amending your offering statement and
providing the
requested information. If you do not believe a comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your offering statement and the
information you
provide in response to this letter, we may have additional comments. Unless we
note
otherwise, any references to prior comments are to comments in our July 7, 2025
letter.

Amendment No. 4 to Offering Statement on Form 1-A
Plan of Operations
Memorandum of Understanding with AI Developer, Augere Medical AS, page 39

1.     We note your disclosure that you have entered into a memorandum of
understanding
       with AI developer Augere Medical AS. Please state clearly if this
memorandum of
       understanding is binding or not. Additionally, please file this
memorandum of
       understanding as an exhibit or tell us why you believe you are not
required to do so.
       Please refer to Item 17(6) of Part III of Form 1-A.
2.     We note your disclosure that you intend to make a $2,000,000 investment
into
       Augere in return for a 10% equity stake in Augere and that you intend to
make certain
       milestone payments to Augere totaling $1,250,000. Given that this is a
best efforts
       offering and you are not employing a minimum offering amount, please
disclose how
 July 29, 2025
Page 2

       you will proceed if you do not raise enough funds to cover all of these
costs. Your
       disclosure should also address whether you would move forward with a
minority
       investment into Augere if the size of the investment relative to your
total assets would
       give rise to potential concerns about you operating as an unregistered
investment
       company under the Investment Company Act of 1940. Additionally, please
revise
       your Use of Proceeds disclosure to reflect the payments to Augere.
        Please contact Kristin Lochhead at 202-551-3664 or Terence O'Brien at
202-551-3355
if you have questions regarding comments on the financial statements and
related
matters. Please contact Nicholas O'Leary at 202-551-4451 or Conlon Danberg at
202-551-
4466 with any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of
Industrial Applications and
                                                            Services
cc:   Conn Flanigan, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._